Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) have been given an average recommendation of “Moderate Buy” by the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $19.5714.

ADPT has been the topic of several research reports. TD Cowen upped their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Morgan Stanley lowered their price objective on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. JPMorgan Chase & Co. lowered their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Finally, BTIG Research restated a “buy” rating and set a $22.00 price objective on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th.

Adaptive Biotechnologies Trading Down 0.8%

ADPT opened at $17.46 on Tuesday. The company’s fifty day moving average price is $14.62 and its two-hundred day moving average price is $15.63. Adaptive Biotechnologies has a 1-year low of $9.96 and a 1-year high of $20.76. The company has a market cap of $2.79 billion, a price-to-earnings ratio of -52.91 and a beta of 2.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same quarter in the prior year, the company posted ($0.20) earnings per share. The business’s revenue was up 35.1% on a year-over-year basis. As a group, equities analysts forecast that Adaptive Biotechnologies will post -0.47 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Julie Rubinstein sold 30,941 shares of the company’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $14.83, for a total value of $458,855.03. Following the completion of the sale, the chief operating officer owned 434,188 shares in the company, valued at $6,439,008.04. This represents a 6.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Francis Lo sold 39,741 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $17.49, for a total transaction of $695,070.09. Following the completion of the sale, the insider owned 250,934 shares of the company’s stock, valued at approximately $4,388,835.66. The trade was a 13.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 502,594 shares of company stock worth $7,349,096. Insiders own 5.70% of the company’s stock.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors have recently made changes to their positions in the company. 1492 Capital Management LLC bought a new position in Adaptive Biotechnologies during the fourth quarter valued at about $1,484,000. Allianz Asset Management GmbH boosted its position in Adaptive Biotechnologies by 305.8% during the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock worth $4,814,000 after purchasing an additional 242,474 shares during the period. UBS Group AG boosted its position in Adaptive Biotechnologies by 101.6% during the fourth quarter. UBS Group AG now owns 511,927 shares of the company’s stock worth $8,314,000 after purchasing an additional 257,947 shares during the period. Jupiter Asset Management Ltd. boosted its position in Adaptive Biotechnologies by 33.8% during the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after purchasing an additional 91,683 shares during the period. Finally, Affinity Wealth Management LLC bought a new position in Adaptive Biotechnologies during the third quarter worth about $4,541,000. Institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.